Skip to content

The Exploratory Study about Efficacy and Safety of Ninjin'yoeito for Fatigue and Malaise Expressed in Postoperative Patients with Colorectal Cancer

The Exploratory Study about Efficacy and Safety of Ninjin'yoeito for Fatigue and Malaise Expressed in Postoperative Patients with Colorectal Cancer - The Exploratory Study about Efficacy and Safety of Ninjin'yoeito in Postoperative Patients with Colorectal Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000034613
Enrollment
15
Registered
2018-11-15
Start date
2019-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

The administration of Ninjin&#39
yoeito

Sponsors

University of Toyama
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with resected colorectal cancer (clinical stage I to IIIb) 2) Patients with Grade 1 or higherfatigue or malaise after surgery (CTCAE ver. 4.0) 3) Patients with ECOG PS 0 to 2 4) Patients whose main organ functions are adequately maintained 5) Age: over 80 years old (when acquiring consent) 6) Category of examination: Outpatient and hospitalization 7) Patients who can be orally administered 8) Patients who wrote consent form to participate in this study

Exclusion criteria

Exclusion criteria: 1) Patients with active other cancers 2) Patients with severe complications (such as liver disease, renal disease, heart disease, blood disease or metabolic disease) or mental disease 3) Patients taking drugs banned in this study or Ninjin'yoeito within 4 weeks before the start of the study 4) Patients who have a history of allergies to traditional Chinese medicine

Design outcomes

Primary

MeasureTime frame
Fatigue and Malaise: The Evaluation by Chaludder fatigue questionnaire

Countries

Japan

Contacts

Public ContactBaba Hayato

Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama Department of Surgery and Science

hayato.bb@gmail.com076-434-7331

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026